SLV308 for Treatment of Patients With Early Parkinson's Disease
Completed · Phase 3 · Has a placebo group
Conditions studied: Early Stage Parkinson's Disease
In brief
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Key facts
- Study ID
- NCT00269516
- Run by
- Solvay Pharmaceuticals
- People needed
- 468
- Starts
- 2006-06-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2008-08-29
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of idiopathic Parkinson's Disease,
- Early stage of disease, Modified Hoehn \& Yahr up to stage III,
- UPDRS motor score (part III) 10 at baseline.
You may not qualify if…
- Diagnosis is unclear or a suspicion of other parkinsonian syndromes,
- Patients who have undergone surgery for the treatment of PD,
- Presence of dyskinesias,
- Motor fluctuations or loss of postural reflexes,
- Clinically significant abnormalities,
- Patients treated with L-dopa or dopamine agonists currently or in the past (for more than 3 months in total),
- Antipsychotic.
Where it is running
- Site 274 — Little Rock, Arkansas, United States
- Site 283 — Fountain Valley, California, United States
- Site 277 — La Jolla, California, United States
- Site 271 — San Francisco, California, United States
- Site 279 — Fort Lauderdale, Florida, United States
- Site 293 — Gainsville, Florida, United States
- Site 282 — Port Charlotte, Florida, United States
- Site 285 — Sunrise, Florida, United States
- Site 273 — Tampa, Florida, United States
- Site 290 — Chicago, Illinois, United States
- Site 280 — Kansas City, Kansas, United States
- Site 292 — Bingham Farms, Michigan, United States
- Site 275 — Traverse City, Michigan, United States
- Site 276 — St Louis, Missouri, United States
- Site 287 — St Louis, Missouri, United States
- Site 278 — Las Vegas, Nevada, United States
- Site 286 — Rochester, New York, United States
- Site 288 — Ashville, North Carolina, United States
- Site 289 — Charlotte, North Carolina, United States
- Site 294 — Toledo, Ohio, United States
- Site 281 — Pittsburgh, Pennsylvania, United States
- Site 291 — Warwick, Rhode Island, United States
- Site 272 — Houston, Texas, United States
- Site 201 — Buenos Aires, Argentina
- Site 284 — Huntsville, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.